Eisai halted Phase 3 development of lorcaserin for Dravet syndrome due to recruitment challenges. The drug was previously ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback